Product image of Iricryn (Bimatoprost) supplied by GNH India

Iricryn

Active Ingredient:
Bimatoprost
Origin:
EU

Iricryn (Bimatoprost)

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. Approved in the European Union, it lowers intra‑ocular pressure to manage open‑angle glaucoma and ocular hypertension in adult patients.

GNH India supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory adherence, and reliable logistics for global eye‑care providers. Our distribution network covers Europe, Asia, Africa and the Americas, facilitating timely delivery and support for clinical practice.

Manufacturer / TM Owner

Brill Pharma Unipessoal Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iricryn, a prostaglandin analog, is used to manage conditions that involve elevated intra‑ocular pressure.

  • Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
  • Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma.
  • Elevated intra‑ocular pressure: provides pressure reduction in patients at risk of developing glaucoma.

How It Works

  • Bimatoprost acts as a prostaglandin F2α analog that binds to prostanoid FP receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor. By increasing this unconventional drainage pathway, the drug effectively reduces intra‑ocular pressure, helping to control glaucoma and ocular hypertension.

Side Effects

Iricryn may cause a range of ocular reactions, most of which are mild and transient.

Common Side Effects

  • Eye redness: mild conjunctival hyperemia.
  • Eye itching or irritation: transient discomfort after instillation.
  • Increased eyelash growth: longer, thicker lashes may develop.
  • Darkening of iris: gradual increase in iris pigmentation.

Serious or Rare Side Effects

  • Uveitis: inflammation of the uveal tract requiring medical attention.
  • Macular edema: swelling of the central retina that can affect vision.
  • Vision loss: rare but severe decrease in visual acuity.
  • Severe allergic reaction: swelling, rash, or difficulty breathing.

Precautions & Warnings

Before using Iricryn, consider the following safety measures.

  • Monitor intra‑ocular pressure: schedule regular measurements to assess therapeutic response.
  • Assess for ocular infections: avoid use in eyes with active infection or inflammation.
  • Discontinue contact lens wear: remove lenses before and for at least 15 minutes after instillation.
  • Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
  • Systemic absorption caution: be vigilant in patients with asthma or known hypersensitivity to prostaglandins.
  • Store at room temperature: keep in the original container, protect from light and moisture.

Avoid Interactions

Iricryn can interact with other ocular or systemic agents; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Concomitant prostaglandin analogs: additive pressure‑lowering effect may cause excessive IOP reduction.
  • Preservative‑containing anesthetic drops: increased risk of corneal toxicity.
  • Systemic carbonic anhydrase inhibitors: may diminish the IOP‑lowering efficacy of Bimatoprost.

Moderate Interactions (Monitor Closely)

  • Topical non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation.
  • Topical beta‑blockers: additive IOP‑lowering effect warrants careful monitoring.

Frequently Asked Questions

Iricryn is a prescription ophthalmic solution containing bimatoprost. It is indicated for the treatment of open‑angle glaucoma and ocular hypertension, conditions where lowering intra‑ocular pressure helps prevent optic nerve damage and preserve vision.

Bimatoprost is a prostaglandin F2α analog that binds to FP receptors in the eye’s ciliary body. This binding increases uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure and helping to control glaucoma and ocular hypertension.

The dosing regimen for Iricryn is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

The safety of Iricryn in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Iricryn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iricryn (bimatoprost) belongs to the prostaglandin analog class, similar to latanoprost and travoprost. All three lower intra‑ocular pressure by enhancing uveoscleral outflow, but bimatoprost may produce a slightly greater pressure‑lowering effect in some patients, while having a comparable safety profile.

Store Iricryn at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from light and moisture, and do not freeze. If the solution becomes discolored or particles appear, discard it and obtain a new supply.

Iricryn is applied as a single drop to the conjunctival sac of the affected eye(s) once daily, usually in the evening. The patient should wash hands, avoid touching the tip of the bottle to the eye or any surface, and wait a few minutes before applying other eye medications.

Serious risks, though rare, include uveitis (inflammation of the eye’s middle layer), macular edema (swelling of the central retina), severe allergic reactions, and significant vision loss. Any sudden change in vision, eye pain, or persistent redness should prompt immediate medical evaluation.

Iricryn is contraindicated in patients with known hypersensitivity to bimatoprost or any component of the formulation, and in eyes with active intra‑ocular inflammation or infection. Caution is also advised for patients with a history of severe asthma or those using certain systemic carbonic anhydrase inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Bimatoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT